Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms’ Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients

EJHaem Pub Date : 2025-05-14 DOI:10.1002/jha2.70048

Masahiro Ogasawara, Mamiko Miyashita, Yuka Yamagishi, Shuichi Ota

{"title":"Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms’ Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients","authors":"Masahiro Ogasawara, Mamiko Miyashita, Yuka Yamagishi, Shuichi Ota","doi":"10.1002/jha2.70048","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Myeloid-derived suppressor cells (MDSCs) play a critical role in immunotherapy.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We investigated the effects of the Wilms' tumor 1 (WT1) peptide-loaded dendritic cell (DC) vaccination on MDSCs in patients with acute leukemia.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>WT1-DC vaccination reduced MDSCs and enhanced WT1-specific immunity. In complete remission patients, MDSC reduction was accompanied by decreased arginase 1 and indoleamine 2,3-dioxygenase levels and increased interleukin (IL)-12 and interferon-γ levels in plasma. Conversely, patients with disease progression showed increased IL-10 and transforming growth factor-β1. Reduced MDSCs were correlated with WT1-specific immune activation and associated with longer survival.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These findings indicate that WT1-DC vaccination suppresses MDSCs and improves clinical outcomes.</p>\n </section>\n \n <section>\n \n <h3> Clinical Trial Registration</h3>\n \n <p>This study is registered with the University Hospital Medical Information Network (UMIN) in Japan (Registration ID: UMIN000027279).</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70048","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Myeloid-derived suppressor cells (MDSCs) play a critical role in immunotherapy.

Methods

We investigated the effects of the Wilms' tumor 1 (WT1) peptide-loaded dendritic cell (DC) vaccination on MDSCs in patients with acute leukemia.

Results

WT1-DC vaccination reduced MDSCs and enhanced WT1-specific immunity. In complete remission patients, MDSC reduction was accompanied by decreased arginase 1 and indoleamine 2,3-dioxygenase levels and increased interleukin (IL)-12 and interferon-γ levels in plasma. Conversely, patients with disease progression showed increased IL-10 and transforming growth factor-β1. Reduced MDSCs were correlated with WT1-specific immune activation and associated with longer survival.

Conclusion

These findings indicate that WT1-DC vaccination suppresses MDSCs and improves clinical outcomes.

Clinical Trial Registration

This study is registered with the University Hospital Medical Information Network (UMIN) in Japan (Registration ID: UMIN000027279).

Abstract Image

查看原文本刊更多论文

Wilms肿瘤1靶向树突状细胞疫苗减少髓源性抑制细胞对急性白血病患者临床结局的影响

骨髓源性抑制细胞（MDSCs）在免疫治疗中起着关键作用。方法研究装载WT1肽的树突状细胞（DC）疫苗接种对急性白血病患者MDSCs的影响。结果接种WT1-DC疫苗可减少MDSCs，增强wt1特异性免疫。在完全缓解的患者中，MDSC减少伴随着血浆精氨酸酶1和吲哚胺2,3-双加氧酶水平的降低和白细胞介素(IL)-12和干扰素-γ水平的升高。相反，疾病进展的患者IL-10和转化生长因子-β1升高。减少的MDSCs与wt1特异性免疫激活相关，并与更长的生存期相关。结论接种WT1-DC可抑制MDSCs，改善临床预后。本研究已在日本大学医院医疗信息网（UMIN）注册（注册ID: UMIN000027279）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量